Document Type : original article


1 Department of Pediatric Endocrinology, Arak University of Medical Sciences, clinical research development center of Amirkabir Hospital, Arak, Iran

2 Student research committee, Arak university of medical science, Arak, Iran

3 Amirkabir hospital, Department of Pediatric Nephrology, School of Medicine, Arak University of Medical Sciences, Arak, Iran.


Background: Nephrotic Syndrome (NS), common in the pediatric population is typically treated with high-dose glucocorticoid (GC). Long-term GC treatment in refractory cases results in osteoporosis susceptibility. Immunosuppressants adjuvant to GC, used to induce remission in steroid-resistant NS, have shown controversial effects on bone density. This study aims to evaluate and compare bone density in children with NS undergoing GC therapy for ≥2 years with or without immunosuppression using DEXA.
Methods: Twenty-three NS patients were enrolled in the study and underwent DXA scan. Demographic data and years of disease, and electrolytes including calcium, phosphorus, and vitamin D levels, as well as creatinine, Glomerular Filtration Rate (GFR), and albumin were documented.
Results: DEXA scan showed low bone density in 4 out of 23 participants (17.4%), two of whom had scores lower than -2, which is indicative of osteoporosis, 2 of whom received cyclosporine and one received tacrolimus adjuvant therapy. Disease chronicity was significantly higher in children with lower whole-body Z-scores. Lower than normal vitamin D levels were detected in 68% of cases.
Conclusion: Our observations revealed a 2:1 ratio of cyclosporine to tacrolimus use in patients in Z-score <-1. We suggest that pediatric patients undergoing ≥2 years of GC therapy, especially in high doses or adjuvant to immunosuppressants, be screened for bone loss using DEXA scan for timely diagnosis and management. Furthermore, clinicians should be aware of the beneficial effects of vitamin D supplements in long-term GC therapy and evaluate their patients for vitamin D and calcium deficiency.


  1. Hodson, E.M., N.S. Willis, and J.C. Craig, Non‐corticosteroid treatment for nephrotic syndrome in children. Cochrane Database of Systematic Reviews, 2008(1).
  2. Van Staa T, Cooper C, Leufkens H G M, Bishop N, Children and the risk of fractures caused by oral corticosteroids. Journal of bone and mineral research, 2003. 18 (5): p. 913-918.
  3. Bartl, R. and C. Bartl, Bone disorders: Biology, diagnosis, prevention, therapy. 2016: Springer.
  4. Wang, Q. and E. Seeman, Skeletal growth and peak bone strength. Best Practice & Research Clinical Endocrinology & Metabolism, 2008. 22(5): p. 687-700.
  5. Canalis E, Mazziotti G, Giustina A, Bilezikian J P, Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis International, 2007. 18(10): p. 1319-1328.
  6. Ventura A, Brunetti G, Colucci S, Oranger A, Ladisa F, Cavallo L, Grano M, Faienza MF, Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency. BioMed Research International, 2013. 2013.
  7. Faienza MF, Brunetti G, Colucci S, Piacente L, Ciccarelli M, Giordani L, Del Vecchio GC, D'Amore M, Albanese L, Cavallo L, Grano M, Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance. The Journal of Clinical Endocrinology & Metabolism, 2009. 94(7): p. 2269-2276.
  8. Grover, M. and L.K. Bachrach, Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment. Current Osteoporosis Reports, 2017. 15(4): p. 271-282.
  9. Griswold W R, Tune B M, Reznik V M, Vazquez M, Prime D J, Brock P, Mendoza S A, Treatment of childhood prednisone-resistant nephrotic syndrome and focal segmental glomerulosclerosis with intravenous methylprednisolone and oral alkylating agents. Nephron, 1987. 46(1): p. 73-7.
  10. Grotz W H, Mundinger F A, Gugel B, Exner V M, Kirste G, Schollmeyer P J, Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation, 1995. 59(7): p. 982-986.
  11. Thiébaud D, Krieg M A, Gillard-Berguer D, Jacquet A F, Goy J J, Burckhardt P, Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. European journal of clinical investigation, 1996. 26(7): p. 549-555.
  12. Stempfle HU, Werner C, Siebert U, Assum T, Wehr U, Rambeck WA, Meiser B, Theisen K, Gärtner R, The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol1. Transplantation, 2002. 73(4).
  13. Goffin E, Devogelaer JP, Lalaoui A, Depresseux G, De Naeyer P, Squifflet JP, Pirson Y, Ypersele de Strihou Cv, Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transplant international, 2002. 15: p. 73-80.
  14. Dimai, H.P., Use of dual-energy X-ray absorptiometry (DXA) for diagnosis and fracture risk assessment; WHO-criteria, T-and Z-score, and reference databases. Bone, 2017. 104: p. 39-43.
  15. Lenchik L, Leib ES, Hamdy RC, Binkley NC, Miller PD, Watts NB, Position Development Conference. South Med J, 2003. 96(7): p. 724-5.
  16. Sambrook, P.N., Inhaled corticosteroids, bone density, and risk of fracture. Lancet, 2000. 355(9213): p. 1385.
  17. Soliman ASA, Abukhatwah MW, Kamal NM, Sweed EMM, Alelyani AM, Althobaiti SD, Alzaedi MA, El-Rebigi AM, Besher NT, Abukhatwah OMW, Alharbi AO, Afifi WE, Bone densitometry in children with idiopathic nephrotic syndrome on prolonged steroid therapy: A tertiary multicenter study. Medicine (Baltimore), 2022. 101(33): p. e29860.
  18. Jesmin T, Mamun AA, Rahman MdA, Santa SM, Huque SS, Begum A, Roy R, Rahman MH, Uddin GM, Bone mineral density in children with relapsing nephrotic syndrome: A hospital-based study. Saudi J Kidney Dis Transpl, 2019. 30(6): p. 1415-1422.
  19. Sharawat IK, Dawman L, Kumkhaniya MV, Devpura K, Mehta A, Bone mineral density and its influencing factors in children with idiopathic nephrotic syndrome: a prospective observational study. Trop Doct, 2019. 49(4): p. 292-298.
  20. Marcén R, Caballero C, Pascual J, Teruel JL, Tenorio M, Ocaña J, Villafruela JJ, Burgos, Ana María Fernández FJ, Muriel A, Ortuño J, Lumbar Bone Mineral Density in Renal Transplant Patients on Neoral and Tacrolimus: A Four-Year Prospective Study. Transplantation, 2006. 81(6): p. 826-831.
  21. Scolapio JS, DeArment J, Hurley DL, Romano M, Harnois D, Weigand SD, Influence of tacrolimus and short-duration prednisone on bone mineral density following liver transplantation. Journal of Parenteral and Enteral Nutrition, 2003. 27(6): p. 427-432.
  22. Shimizu C, Fujita T, Fuke Y, Yabuki M, Kajiwara M, Hemmi S, Satomura A, Soma M, Effects of cyclosporine on bone mineral density in patients with glucocorticoid-dependent nephrotic syndrome in remission. Int Urol Nephrol, 2013. 45(3): p. 803-8.
  23. Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A, Efficacy and Safety of Tacrolimus versus Cyclosporine in Children with Steroid-Resistant Nephrotic Syndrome: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2009. 53(5): p. 760-769.
  24. Gulati S, Sharma RK, Gulati K, Singh U, Srivastava A, Longitudinal follow-up of bone mineral density in children with nephrotic syndrome and the role of calcium and vitamin D supplements. Nephrology Dialysis Transplantation, 2005. 20(8): p. 1598-1603.
  25. Bak, M., E. Serdaroglu, and R. Guclu, Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome. Pediatric Nephrology, 2006. 21(3): p. 350-354.
  26. Neha Sinha, P.W., Biochemical bone markers in children with steroid sensitive nephrotic syndrome in remission. International Journal of Contemporary Pediatrics, 2018. 5(4).